GI Pharmacology: Laxatives and Antidiarrheals

Introduction / Overview

Gastrointestinal motility disorders, ranging from constipation to acute diarrhoea, represent a common clinical challenge with significant morbidity and impact on quality of life. Laxatives and antidiarrheals constitute the cornerstone of symptomatic therapy for these conditions. Their widespread use, diverse mechanisms, and variable safety profiles necessitate a thorough understanding for clinicians and pharmacists alike. This chapter offers a systematic review of the pharmacology of these agents, encompassing classification, pharmacodynamics, pharmacokinetics, therapeutic indications, adverse effects, interactions, and special patient populations.

Learning Objectives

• Identify the major classes of laxatives and antidiarrheals and their chemical characteristics.
• Describe the pharmacodynamic mechanisms underlying the therapeutic actions of these agents.
• Summarize key pharmacokinetic parameters that influence dosing regimens.
• Recognize approved indications, off‑label uses, and contraindications for each drug class.
• Understand potential adverse reactions, drug–drug interactions, and special considerations in pregnancy, lactation, pediatrics, geriatrics, and patients with organ dysfunction.

Classification

Classification of Laxatives

Based on their site of action and mechanism, laxatives may be grouped into the following categories:

• Bulk‑forming agents – e.g., psyllium, methylcellulose (increase stool bulk and accelerate transit).
• Osmotic agents – e.g., polyethylene glycol, lactulose, magnesium salts (draw water into the lumen).
• Stimulant laxatives – e.g., senna, bisacodyl (activate enteric nerves to induce peristalsis).
• Lubricant laxatives – e.g., mineral oil (coat stool, reduce friction).
• Secretagogues – e.g., lubiprostone, linaclotide (promote chloride secretion and fluid movement).
• Serotonin‑modulating agents – e.g., plecanatide (increase cyclic nucleotide signaling).

Classification of Antidiarrheals

Antidiarrheals are broadly divided into the following classes:

• Adsorptive agents – e.g., activated charcoal, kaolin‑phosphorus (bind toxins and motilin).
• Motility modulators – e.g., loperamide (μ‑opioid agonist inhibiting gut motility).
• Secretagogues inhibition – e.g., cholera toxin inhibitors (not yet approved clinically).
• Anti‑inflammatory agents – e.g., mesalamine (used in inflammatory bowel disease).

Mechanism of Action

Bulk‑Forming Laxatives

These agents are primarily insoluble fibers that absorb water within the gastrointestinal tract. The resulting increase in stool volume stimulates mechanoreceptors in the colon, thereby enhancing peristaltic activity. The osmotic gradient generated also promotes fluid influx, facilitating stool passage.

Osmotic Laxatives

Osmotic agents remain largely non‑absorbed and exert their effect by increasing the osmolarity of luminal contents. This osmotic shift draws water from the interstitial space into the lumen, softening stool and accelerating transit. For instance, polyethylene glycol is a neutral polymer that binds water molecules, forming a gel that increases stool bulk without significant electrolyte disturbance. Lactulose, a synthetic disaccharide, is fermented by colonic bacteria into short‑chain fatty acids, lowering colonic pH and promoting chloride secretion and subsequent water movement.

Stimulant Laxatives

Stimulants such as senna and bisacodyl act on the enteric nervous system. They activate Aδ and C fibers, leading to increased acetylcholine release from postganglionic parasympathetic fibers. This cholinergic stimulation enhances smooth muscle contraction, thereby accelerating colonic transit. Senna’s active metabolites, primarily glucoside derivatives, mimic the action of endogenous neurotransmitters at muscarinic receptors.

Lubricant Laxatives

Mineral oil forms a slippery coating around the stool, reducing friction against the colonic mucosa and facilitating passage. This mechanical effect is independent of motility or osmotic changes.

Secretagogues

Agents like lubiprostone and linaclotide modulate chloride channels and guanylate cyclase‑C receptors, respectively. Lubiprostone activates chloride channel 2 (ClC‑2) in the intestinal epithelium, promoting chloride and sodium secretion. This osmotic diuretic effect draws water into the lumen, softening stool. Linaclotide binds to guanylate cyclase‑C, increasing cyclic guanosine monophosphate (cGMP) levels, which in turn activates CFTR chloride channels and inhibits sodium absorption, creating a net fluid shift.

Motility Modulators (Antidiarrheals)

Loperamide is a peripherally acting μ‑opioid receptor agonist. It increases intracellular cyclic adenosine monophosphate (cAMP) in smooth muscle cells, leading to decreased intracellular calcium and reduced muscle contraction. This prolongs intestinal transit and increases time available for fluid absorption. Its poor central nervous system penetration limits central opioid effects, thereby reducing abuse potential.

Adsorptive Agents

Activated charcoal possesses a highly porous surface that adsorbs toxins and bacterial products, preventing their absorption. Kaolin‑phosphorus binds motilin, inhibiting the release of this peptide and consequently reducing intestinal motility, which can be beneficial in managing diarrhoea.

Pharmacokinetics

Bulk‑Forming Agents

These fibers are largely non‑absorbable; therefore, systemic exposure is negligible. The pharmacokinetic profile is dominated by transit time through the gastrointestinal tract, typically 24–48 hours. Their effect is immediate upon ingestion and persists as long as adequate hydration is maintained.

Osmotic Laxatives

Polyethylene glycol is minimally absorbed (<1 %) and is excreted unchanged via the feces. Its half‑life is not clinically relevant due to lack of systemic involvement. Lactulose is absorbed in the small intestine and metabolized by colonic bacteria; it has a dose‑dependent effect that can be titrated based on stool frequency. The pharmacokinetic parameters of lactulose are influenced by colonic transit time and bacterial composition.

Stimulant Laxatives

Senna’s active metabolites (e.g., aloe-emodin) are absorbed and undergo hepatic metabolism. The apparent half‑life of senna is approximately 1–2 h, with peak plasma concentrations occurring 30–60 min post‑dose. Bisacodyl is absorbed rapidly from the gastrointestinal tract, with a half‑life of 12–16 h. Both drugs are largely metabolized by the liver and excreted via bile and urine.

Lubricant Laxatives

Mineral oil is poorly absorbed; however, a small fraction may enter systemic circulation via the portal vein. In patients with liver disease, impaired metabolism can lead to accumulation, necessitating dose adjustments. The half‑life of mineral oil is largely dependent on gastric emptying and intestinal transit rates.

Secretagogues

Lubiprostone is absorbed slowly, with a half‑life of approximately 2 h. It is metabolized by hepatic enzymes, primarily CYP3A4, and excreted via biliary and renal routes. Linaclotide is minimally absorbed; its pharmacokinetic profile is dominated by local intestinal action, with negligible systemic exposure. Its half‑life is not clinically significant due to its local, transient effects.

Motility Modulators (Antidiarrheals)

Loperamide is poorly absorbed from the gut lumen, with a half‑life of 3–4 h. It undergoes extensive first‑pass metabolism via CYP3A4 and is excreted in feces. Its pharmacokinetics are dose‑dependent, and accumulation can occur with high doses or prolonged use.

Adsorptive Agents

Activated charcoal is not absorbed; its action is confined to the gastrointestinal tract. Kaolin‑phosphorus is minimally absorbed and is eliminated primarily via feces. The pharmacokinetic parameters are largely dependent on transit time and dosage formulation.

Therapeutic Uses / Clinical Applications

Bulk‑Forming Agents

• Management of chronic constipation, irritable bowel syndrome with constipation (IBS‑C), and fecal impaction.
• Adjunctive therapy in polypharmacy to mitigate constipation induced by opioids or anticholinergics.
• Use in postoperative patients to prevent constipation-related complications.

Osmotic Laxatives

• Short‑term relief of constipation and fecal impaction.
• Preoperative bowel cleansing protocols.
• Lactulose is also employed in hepatic encephalopathy to reduce ammonia absorption.

Stimulant Laxatives

• Acute constipation management in adults and pediatric patients.
• Treatment of fecal impaction when other agents are ineffective.
• Emergency bowel evacuation in acute surgical settings.

Lubricant Laxatives

• Adjunctive treatment for constipation, particularly in patients with slow transit.
• Use in patients with colonic pseudo‑obstruction or Hirschsprung disease.

Secretagogues

• Chronic constipation, including IBS‑C and functional constipation in adults.
• Management of constipation in patients with opioid use disorder or neurogenic bowel.
• Off‑label use in pediatric constipation with careful monitoring.

Motility Modulators (Antidiarrheals)

• Acute infectious diarrhoea in adults and children, with caution in dysentery.
• Management of irritable bowel syndrome with diarrhoea (IBS‑D).
• Adjunctive therapy in inflammatory bowel disease flare-ups to reduce stool frequency.

Adsorptive Agents

• Toxin‑mediated diarrhoea, including cholera, giardiasis, and coccidiosis.
• Management of acute gastrointestinal bleeding in combination with hemostatic agents.

Adverse Effects

Bulk‑Forming Agents

Common side effects include abdominal cramping, bloating, and flatulence. Rarely, excessive use may lead to bowel obstruction, particularly in patients with a history of colonic strictures.

Osmotic Laxatives

Polyethylene glycol is generally well tolerated; mild nausea and abdominal discomfort are reported. Lactulose may cause bloating, flatulence, and, in high doses, electrolyte disturbances (hypernatremia, hypokalemia). Magnesium salts can induce hypermagnesemia, particularly in renal impairment.

Stimulant Laxatives

Stimulants may cause abdominal cramping, diarrhea, and, with chronic use, electrolyte imbalances (hypokalemia). Senna has been associated with rare cases of pseudo‑cholinergic toxicity. Bisacodyl can produce nausea, vomiting, and, in rare instances, severe abdominal pain.

Lubricant Laxatives

Mineral oil may cause steatorrhea, malabsorption of fat‑soluble vitamins, and in rare cases, inadvertent aspiration pneumonia. Long‑term use can increase the risk of systemic mineral oil absorption, leading to hyperlipidemia.

Secretagogues

Lubiprostone may produce nausea, vomiting, and, rarely, hypotension. Linaclotide is generally well tolerated; the most common adverse event is abdominal pain, which may be dose‑dependent.

Motility Modulators (Antidiarrheals)

Loperamide is associated with constipation, abdominal discomfort, and, in high doses, central opioid effects such as sedation or respiratory depression. Rare cases of pseudo‑cholinergic toxicity and severe central nervous system depression have been reported in patients with renal or hepatic impairment.

Adsorptive Agents

Activated charcoal may cause constipation, diarrhea, or, infrequently, intestinal obstruction. Kaolin‑phosphorus can lead to hypophosphatemia and, in severe cases, osteomalacia when used chronically.

Drug Interactions

Bulk‑Forming and Osmotic Laxatives

Fiber preparations may delay absorption of co‑administered drugs. Polyethylene glycol can reduce the bioavailability of oral medications by up to 30 % when taken concurrently. Lactulose may interact with antibiotics, altering gut flora and affecting drug metabolism.

Stimulant Laxatives

Sennoside metabolites inhibit CYP3A4, potentially increasing plasma concentrations of drugs metabolized by this pathway, including certain benzodiazepines and statins. Bisacodyl may potentiate the effects of anticholinergic agents, leading to increased risk of dry mouth and blurred vision.

Lubricant Laxatives

Mineral oil can interfere with absorption of fat‑soluble vitamins (A, D, E, K) and other lipophilic drugs such as warfarin, potentially reducing therapeutic efficacy.

Secretagogues

Lubiprostone is a substrate of CYP3A4; co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole) can increase systemic exposure. Linaclotide has minimal systemic absorption but may be affected by drugs that alter intestinal transit (e.g., prokinetics).

Motility Modulators (Antidiarrheals)

Loperamide should not be combined with potent CYP3A4 inhibitors (e.g., ritonavir) or inducers (e.g., rifampicin) due to altered plasma levels. Concomitant use with other opioids may increase the risk of respiratory depression. Kaolin‑phosphorus may interfere with electrolyte balance when combined with diuretics.

Adsorptive Agents

Activated charcoal can adsorb a wide range of drugs, reducing their systemic absorption. Timing of charcoal administration relative to other medications should be carefully planned to avoid therapeutic failure. Kaolin‑phosphorus may reduce the absorption of certain antibiotics, affecting their efficacy.

Special Considerations

Use in Pregnancy and Lactation

Bulk‑forming agents (psyllium, methylcellulose) are generally considered safe during pregnancy and lactation, provided adequate hydration is maintained. Osmotic laxatives such as polyethylene glycol are also regarded as Category B. Lactulose requires careful monitoring for fluid and electrolyte shifts. Stimulant laxatives should be used with caution; senna is Category C and bisacodyl is Category B but may be contraindicated in severe constipation. Mineral oil is not recommended due to potential for aspiration. Secretagogues lack robust pregnancy data; usage should be individualized. Loperamide is Category C; it is generally avoided in second and third trimester unless benefits outweigh risks. Activated charcoal is Category C but may be used when necessary; kaolin‑phosphorus has limited data but is generally avoided.

Pediatric Considerations

Children require age‑appropriate dosing and formulations. Bulk‑forming agents and osmotic laxatives are commonly used, with doses adjusted for weight (e.g., polyethylene glycol 0.45 g/kg). Stimulant laxatives are typically reserved for acute constipation or fecal impaction. Secretagogues are used off‑label in pediatric constipation with close monitoring. Loperamide is generally contraindicated in children under 12 years due to risk of serious adverse events.

Geriatric Considerations

Older adults may exhibit altered pharmacokinetics due to decreased renal and hepatic function. Dosing should be adjusted accordingly, particularly for agents with renal excretion (magnesium salts, loperamide). Polypharmacy increases the risk of drug interactions; careful review of concurrent medications is warranted. Monitoring for constipation is essential to prevent complications such as fecal impaction or bowel obstruction.

Renal and Hepatic Impairment

Renal dysfunction may impair the clearance of magnesium salts, leading to hypermagnesemia. Loperamide and loperamide metabolites are primarily excreted via the kidneys; dose reductions or avoidance are recommended in severe renal impairment (eGFR < 30 mL/min). Hepatic impairment reduces clearance of drugs metabolized by CYP3A4 (loperamide, lubiprostone). In patients with advanced liver disease, mineral oil absorption may increase, necessitating caution. Lactulose remains an effective agent for hepatic encephalopathy; dosing adjustments are generally not necessary, but monitoring for fluid shifts is advised.

Summary / Key Points

• Laxatives and antidiarrheals cover a spectrum of mechanisms, from mechanical bulk formation to targeted modulation of ion channels and motility pathways.
• Pharmacokinetics vary widely: many agents remain largely unabsorbed, while others undergo hepatic metabolism and renal excretion.
• Therapeutic indications range from chronic constipation and IBS to acute infectious diarrhoea and hepatic encephalopathy.
• Adverse effect profiles differ by class; vigilance for electrolyte disturbances, constipation, and rare systemic toxicity is essential.
• Drug interactions are common, particularly with agents affecting CYP3A4 and those that adsorb in the gut; timing of administration should be carefully managed.
• Special populations—pregnant women, children, elderly, and patients with organ dysfunction—require dose adjustments, monitoring, and, in some cases, avoidance of specific agents.
• Clinical decision‑making should balance efficacy, safety, and patient-specific factors, with an emphasis on individualized therapy and monitoring for adverse events.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.